Bird & Bird has advised Heidelberg-based Exciva GmbH, a clinical biotech company which is developing a novel therapy for the treatment of agitation and aggression in Alzheimer's disease, in its Series A financing led by Andera Partners amounting to EUR 9 million. LBBW Venture Capital and Cure8 also participated in the financing round.
The initial funding will be used by Exciva to develop its lead product to Phase I completion. The compound is a combination of two clinically approved products that have a proven efficacy in treating the central nervous system.
Exciva GmbH was advised by the following Bird & Bird lawyers: Associate Marcel Nurk, partner Stefan Münch and counsel Michael Gaßner, all corporate law/M&A, Munich.
